The goal of this activity is for learners to be better able to compare the prognostic utility for median overall survival (OS) of the 2017 and 2022 European Leukemia Net (ELN) risk classifications with that of bioinformatic algorithm-derived new molecular signatures, based on a pooled analysis of newly diagnosed AML patients in the phase 3 VIALE-A trial (NCT02993523) and phase 1b study (NCT02203773), including 279 patients treated with venetoclax-azacitidine and 113 patients treated with placebo-azacitidine.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1001918
- Start Date: 2024-11-21 06:00:00
- End Date: 2024-11-21 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Journal-based CE
- CME Finder Type: Other
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology
Subscribe
Login
0 Comments
Oldest